Oportuzumab monatox

Oportuzumab monatox
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized
Target	EpCAM
Clinical data
Trade names	Vicineum
ATC code	L01FX16 (WHO) ;
Identifiers
CAS Number	945228-48-8 ;
DrugBank	DB05319 ;
ChemSpider	none;
UNII	945CY7ZMI2;
KEGG	D11913;
Chemical and physical data
Formula	C3072H4723N877O952S12
Molar mass	69558.48 g·mol−1
	(what is this?)

Oportuzumab monatox (proposed INN, trade name Vicineum) is an antineoplastic. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).^[1]

The drug was originally developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016 which then changed its name to Sesen Bio.^[2] In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).^[3] The Company applied for approval of Vicineum by the United States Food and Drug Administration und the European Medicines Agency.

References[]

^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
^ Alex Keown: Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies. Biospace.com, May 16, 2018.
^ Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer. Businesswire.com, August 08, 2019

Vol 24, No 18S (June 20 Supplement), 2006: 4580

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.

[2] Alex Keown: Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies. Biospace.com, May 16, 2018.

[3] Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer. Businesswire.com, August 08, 2019

[1]

[2]

[3]